Dasatinib as a Network-modulating Tyrosine Kinase Inhibitor in Philadelphia Chromosome-positive Leukemias: Integration of BCR-ABL1, SRC, and MAPK Signaling
Philadelphia chromosome-positive leukemias involve signaling systems beyond BCR-ABL1, and treatment response may depend on this wider network biology. Second-generation BCR-ABL1 tyrosine kinase inhibitors such as dasatinib, nilotinib, and bosutinib show variable clinical responses according to diagnosis and disease sta...